The rare bone dis­ease drug be­ing de­vel­oped by Ul­tragenyx Phar­ma­ceu­ti­cal and Mereo Bio­Phar­ma has cat­e­gor­i­cal­ly failed in its late-stage pro­gram, the part­ners re­vealed Mon­day. Mereo’s stock MREO fell 90% when the Nas­daq opened on Mon­day morn­ing...